Deutsche Bank AG Decreases Stock Position in Pacira BioSciences, Inc. $PCRX

Key Points

• Deutsche Bank AG significantly reduced its holdings in Pacira BioSciences, cutting its stake by 81.2% in the first quarter, leaving it with approximately 330,578 shares valued at $8.2 million.
• Several other institutional investors, such as Sterling Capital Management and US Bancorp DE, have made notable adjustments to their positions in Pacira BioSciences, highlighting a shift in investment interest.
• Analysts maintain a consensus rating of "Moderate Buy" for Pacira BioSciences, with price targets around $30.83, despite recent adjustments to targets by firms like Needham & Company LLC.

Deutsche Bank AG lessened its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 81.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 330,578 shares of the company's stock after selling 1,425,828 shares during the period. Deutsche Bank AG owned approximately 0.71% of Pacira BioSciences worth $8,215,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Geode Capital Management LLC grew its position in Pacira BioSciences by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,091,970 shares of the company's stock worth $20,578,000 after purchasing an additional 5,071 shares during the period. Point72 Asset Management L.P. bought a new stake in Pacira BioSciences in the 4th quarter worth approximately $20,266,000. Assenagon Asset Management S.A. grew its position in Pacira BioSciences by 48.9% in the 1st quarter. Assenagon Asset Management S.A. now owns 673,289 shares of the company's stock worth $16,731,000 after purchasing an additional 221,196 shares during the period. Nuveen Asset Management LLC grew its position in Pacira BioSciences by 109.9% in the 4th quarter. Nuveen Asset Management LLC now owns 625,917 shares of the company's stock worth $11,792,000 after purchasing an additional 327,754 shares during the period. Finally, Northern Trust Corp grew its position in Pacira BioSciences by 30.8% in the 4th quarter. Northern Trust Corp now owns 616,891 shares of the company's stock worth $11,622,000 after purchasing an additional 145,205 shares during the period. Institutional investors own 99.73% of the company's stock.

Analyst Ratings Changes

A number of research firms have commented on PCRX. Wall Street Zen raised shares of Pacira BioSciences from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. Needham & Company LLC cut their price objective on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Truist Financial raised shares of Pacira BioSciences from a "hold" rating to a "buy" rating and set a $30.00 price objective for the company in a research report on Friday, July 25th. Finally, Zacks Research raised shares of Pacira BioSciences from a "strong sell" rating to a "hold" rating in a research report on Thursday, August 14th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, Pacira BioSciences currently has an average rating of "Moderate Buy" and a consensus price target of $30.83.

Insider Buying and Selling at Pacira BioSciences

In related news, Director Marcelo Bigal sold 4,912 shares of the company's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $23.67, for a total value of $116,267.04. Following the completion of the transaction, the director owned 11,393 shares of the company's stock, valued at approximately $269,672.31. This represents a 30.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Lauren Riker sold 5,578 shares of the company's stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $26.21, for a total transaction of $146,199.38. Following the completion of the transaction, the senior vice president directly owned 59,564 shares of the company's stock, valued at $1,561,172.44. This represents a 8.56% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company's stock.

Pacira BioSciences Price Performance

Pacira BioSciences stock traded down $0.1920 during mid-day trading on Wednesday, hitting $24.9980. The stock had a trading volume of 21,772 shares, compared to its average volume of 804,597. The firm has a market capitalization of $1.12 billion, a P/E ratio of -9.02 and a beta of 0.48. The company has a current ratio of 2.38, a quick ratio of 1.91 and a debt-to-equity ratio of 0.50. The firm's 50 day moving average is $23.43 and its 200 day moving average is $24.58. Pacira BioSciences, Inc. has a one year low of $12.61 and a one year high of $27.64.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.01. The company had revenue of $181.10 million during the quarter, compared to the consensus estimate of $183.11 million. Pacira BioSciences had a negative net margin of 18.08% and a positive return on equity of 13.29%. Pacira BioSciences's quarterly revenue was up 1.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.96 EPS. Pacira BioSciences has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Pacira BioSciences, Inc. will post 2.41 earnings per share for the current fiscal year.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.